The high proportion of NK cells that express NKG2A, which increases further after transplantation or ex vivo expansion (16), and the upregulation of HLA-E in certain tumors (17–21), emphasize the need to develop strategies to overcome inhibition of NK cells for use in cancer immunotherapy. The gene discussed is HLA-E; the disease is cancer.